Scandinavian ChemoTech holds the first training session at Ulis Medical Centre in Ukraine
We are pleased to announce that doctors and nurses at the Ulis Medical Centre (Ulis MC) in Zaporizhia, Ukraine attended their first training session with IQwave™ 3.0 CE and TSE yesterday.
Despite the ongoing condemned Russian war against Ukraine, the doctors and nurses continue to serve and treat the country’s cancer patients. Today ChemoTech hosted a 3-hour long, online, training in order to certify them in using the IQwave™, which they acquired a few weeks ago.
Yesterday’s training was performed by ChemoTech’s application specialist in India along with Dr Suhail Mufti from HCG Hospital in Bengaluru.
“The clinic has everything to conduct a quick and high-quality examination, establish a diagnosis and develop and implement an individualized treatment plan for each patient.
The doctors and nurses at Ulis MC are proud and excited to be the first clinic in Ukraine that implements the TSE technology and starts working with the IQwave™ 3.0 CE device developed by ChemoTech.” – says Smirnov Yuri, General Manager at Ulis MC
About Ulis Medical Centre
Since 2006, oncology experts have been working at Ulis MC (www.ulis.zp.ua) - doctors of the highest category, candidates of medical sciences and professors ensure that their patients receive the correct diagnosis and create the optimal treatment plan. They use modern clinical oncology approaches and advanced cancer therapy technologies based on the achievements of post-genomic science and personalized molecular medicine.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
